Indication
Pseudomonas aeruginosa bronchitis
*Pseudomonas aeruginosa* bronchitis is a localized lower respiratory tract infection characterized by acute or chronic inflammation of the bronchial airways caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa*. Read more about Pseudomonas aeruginosa bronchitis
7 drugs 7 manufacturers
Drugs that treat it
Common Pseudomonas aeruginosa bronchitis therapies.
AZTREONAM
AZTREONAM
AZTREONAM
AZTREONAM
AZTREONAM
AZTREONAM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soon*Pseudomonas aeruginosa* bronchitis is a localized lower respiratory tract infection characterized by acute or chronic inflammation of the bronchial airways caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa*.
It primarily affects individuals with compromised respiratory defenses or structural lung disorders, such as cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, or those requiring mechanical ventilation.
Pathophysiologically, the organism establishes infection through adherence to impaired mucosal epithelium and often forms robust alginate-rich biofilms that impair mucociliary clearance and evade host immunity.
Defining clinical features include persistent cough, increased production of thick and often purulent green sputum, worsening dyspnea, wheezing, and progressive airway damage in the absence of parenchymal consolidations characteristic of pneumonia.
- nih.gov
*Pseudomonas aeruginosa* bronchitis is a localized lower respiratory tract infection characterized by acute or chronic inflammation of the bronchial airways caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa*
- merckmanuals.com
*Pseudomonas aeruginosa* bronchitis is a localized lower respiratory tract infection characterized by acute or chronic inflammation of the bronchial airways caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa* It primarily affects individuals with compromised respiratory defenses or structural lung disorders, such as cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, or those requiring mechanical ventilation Pathophysiologically, th...
- nih.gov
It primarily affects individuals with compromised respiratory defenses or structural lung disorders, such as cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, or those requiring mechanical ventilation Pathophysiologically, the organism establishes infection through adherence to impaired mucosal epithelium and often forms robust alginate-rich biofilms that impair mucociliary clearance and evade host immunity Defining clinical features include persistent c...
- cdc.gov
It primarily affects individuals with compromised respiratory defenses or structural lung disorders, such as cystic fibrosis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, or those requiring mechanical ventilation
Personalize your experience
Follow Pseudomonas aeruginosa bronchitis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.